Sagimet grants CEO 300k stock options and 300k performance RSUs tied to regulatory milestones

Filed June 3, 2026 · Period ending May 28, 2026 · ~1 min read

Key Changes

• medium

  CEO David Happel received 300,000 stock options at $7.27/share and 300,000 performance-based RSUs, the largest equity grant among three executives awarded on May 28, 2026.

  Item 5.02 verify on EDGAR →
• medium

  Performance RSUs vest only upon achieving unspecified regulatory milestones, with one-third vesting at achievement and two-thirds over the following two years, directly tying executive pay to drug development progress.

  Item 5.02 verify on EDGAR →
• low

  CFO Thierry Chauche and Chief Legal Officer Elizabeth Rozek received 50,000 and 100,000 options/PSUs respectively, with identical vesting terms.

  Item 5.02 verify on EDGAR →